MedSearchGraphRAG
6 quiz questions available for this topicTake Quiz

Palliative cancer care - pain

SNOMED: 103735009967 words•Updated 03/03/2026
💡

Exam Tips

  • In OSCEs, separate background pain, breakthrough pain, incident pain, and end-of-dose failure; examiners often test this distinction.
  • Assess each pain site individually because patients commonly have multiple simultaneous pains with different mechanisms.
  • Use a validated scale (NRS/VAS) at baseline and after intervention to demonstrate objective reassessment.
  • Acute severe pain in opioid-naive adults: morphine 5 mg SC/slow IV stat (2.5 mg if frail/elderly) while evaluating cause and escalating to specialist care.
  • Always screen for red flags: new focal neurology, bladder/bowel dysfunction, sudden severe bony pain, and rapidly progressive pain pattern.
  • Remember 'total pain': psychological, social, and spiritual factors can amplify symptom burden and must be addressed in management plans.

Definition

Cancer pain in palliative care is a multidimensional symptom syndrome rather than a single diagnosis, arising from tumour effects, cancer treatments, procedures, and coexisting non-malignant disease. It commonly includes background persistent pain plus episodic flares (breakthrough or incident pain), and must be interpreted in biological, psychological, social, and spiritual context to guide safe, individualised management.

Pathophysiology

Most patients have mixed-mechanism pain with overlap between nociceptive and neuropathic processes plus an inflammatory component. Somatic nociceptive pain comes from activation of nociceptors in skin, bone, and soft tissues (for example bone metastases), visceral pain from stretch/distension/infiltration of organs (for example liver capsule stretch or bowel obstruction), and neuropathic pain from peripheral or central neural injury/compression (for example plexus, root, or cord involvement after tumour growth, surgery, or radiotherapy). Central sensitisation and reduced descending inhibition can amplify pain perception, while anxiety, depression, fear, and spiritual distress lower pain tolerance ('total pain' concept). For visual revision, see the pain pathway and WHO analgesic ladder figures in standard UK palliative medicine textbook chapters.

Risk Factors

  • Metastatic, advanced, or terminal cancer stage
  • Cancer types with high early pain burden (for example pancreatic and head and neck cancers)
  • Bone, nerve root, plexus, or spinal involvement by tumour
  • Recent surgery, chemotherapy, radiotherapy, or repeated painful procedures
  • Pre-existing painful comorbidity (for example osteoarthritis, infection-related pain)
  • Psychological distress (anxiety/depression), social isolation, or spiritual distress

Clinical Features

Symptoms

  • Persistent background pain with or without episodic breakthrough flares
  • Incident pain triggered by movement/activity (for example coughing, swallowing, mobilising)
  • Unpredictable spontaneous breakthrough pain not linked to activity
  • End-of-dose pain recurrence just before next opioid dose (suggesting dose interval/amount issue, not true breakthrough)
  • Neuropathic descriptors: burning, shooting, electric-shock pain, allodynia, numbness
  • Sleep disturbance, reduced function, and impaired activities of daily living
  • Patient concern about cause/progression of pain, often with anxiety or low mood

Signs

  • Localised bony tenderness or pain on movement (possible metastasis/pathological fracture)
  • Neurological deficit: sensory change, weakness, altered reflexes, sphincter disturbance (possible cord/nerve compression)
  • Guarding, reduced mobility, positional discomfort
  • Distress behaviours (grimacing, agitation), especially when communication is impaired
  • Signs of opioid adverse effects: sedation, pinpoint pupils, nausea, constipation, myoclonus (dose-related/toxicity concern)

Investigations

Structured pain assessment (NRS/VAS) and pain diary:Baseline severity (mild <3/10, moderate 3-6/10, severe >6/10), temporal pattern, and distinction between background, incident, breakthrough, and end-of-dose pain
Focused clinical examination (site-specific and neurological):Mechanism clues (somatic vs visceral vs neuropathic), red flags for spinal cord compression or pathological fracture
MRI whole spine (urgent if neurological red flags):Epidural disease, vertebral collapse, or metastatic spinal cord/cauda equina compression
Targeted imaging (X-ray/CT/bone imaging as clinically indicated):Bone metastases, fracture, visceral distension/infiltration, or new disease progression
Blood tests (FBC, U&E, eGFR, LFT, calcium, CRP as indicated):Contributors to pain or opioid safety issues (for example hypercalcaemia, renal impairment affecting opioid clearance)

Management

Lifestyle Modifications

  • Assess each pain separately and review regularly; involve patient directly where possible
  • Set shared goals (sleep, mobility, function) and document response using the same pain scale
  • Address psychological/social/spiritual contributors with holistic palliative MDT input
  • Use non-drug supports: positioning, pacing activity, physiotherapy/OT input, and trigger avoidance for incident pain
  • Provide clear safety-net advice for acute severe pain or red flags (new weakness, bladder/bowel symptoms, sudden severe focal pain)

Pharmacological Treatment

Strong opioid for acute severe cancer pain

  • Morphine sulfate 5 mg subcutaneously or by slow IV injection stat if opioid-naive
  • Morphine sulfate 2.5 mg subcutaneously or by slow IV injection stat in frail/elderly opioid-naive patients
  • If already on opioids: calculate 4-hourly opioid requirement from total 24-hour dose (including breakthrough, excluding incident-only doses), then convert to SC morphine (roughly half equivalent oral morphine dose)

Immediate relief first, then urgent specialist palliative review and cause-directed assessment. Monitor respiratory rate, sedation, and blood pressure; have naloxone protocols available for opioid-induced respiratory depression.

Background and breakthrough opioid regimen

  • Morphine oral immediate-release typically 5-10 mg every 4 hours in opioid-naive adults, titrated to effect
  • Breakthrough morphine oral immediate-release usually 1/6 of total 24-hour oral morphine dose PRN
  • Morphine modified-release every 12 hours once stable total daily requirement established

Adjust dose for renal impairment and frailty; consider alternatives (for example oxycodone or fentanyl) if morphine not tolerated or renal function is poor, ideally with specialist advice.

Non-opioid and adjuvant analgesia

  • Paracetamol 1 g every 6 hours (max 4 g/day; lower max in low body weight/frailty/liver risk)
  • Ibuprofen 200-400 mg three times daily if inflammatory component and no contraindication
  • Gabapentin 100-300 mg at night then titrate for neuropathic pain
  • Amitriptyline 10-25 mg at night for neuropathic pain where appropriate

NSAID cautions: CKD, heart failure, peptic ulcer/GI bleed risk, anticoagulants. Neuropathic adjuvants can cause sedation/dizziness; start low and titrate.

Prophylaxis for opioid adverse effects

  • Senna 7.5-15 mg at night (titrate)
  • Macrogol 1-3 sachets daily according to response
  • Metoclopramide 10 mg up to three times daily PRN nausea (if suitable)

Prescribe laxatives routinely with opioids unless contraindicated. Review for persistent nausea, delirium, or constipation suggesting opioid toxicity or bowel obstruction.

Surgical / Interventional

  • Palliative radiotherapy for painful bone metastases
  • Orthopaedic stabilisation/fixation for actual or impending pathological fracture
  • Urgent oncological/neurosurgical pathway for malignant spinal cord compression
  • Interventional pain procedures in selected refractory pain (for example nerve block, neuraxial analgesia) via specialist teams

Complications

  • Undertreated pain causing immobility, sleep loss, depression, and reduced quality of life
  • Opioid toxicity (sedation, respiratory depression, delirium, myoclonus), especially with renal impairment
  • Opioid-induced constipation, nausea, and reduced oral intake
  • Falls and functional decline from pain plus sedating drugs
  • Missed time-critical causes of acute pain (spinal cord compression, pathological fracture, PE, MI, perforated viscus)

Prognosis

Pain is common across the cancer trajectory and increases with advanced disease; many patients achieve meaningful relief with systematic reassessment, mechanism-based treatment, and timely dose titration. Around one in ten patients with advanced/metastatic disease have pain that remains difficult to control and usually need early specialist palliative input and multimodal strategies.

Sources & References

💊BNF Drug References(21)

✅NICE Guidelines(1)

📖Textbook References(20)

  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1778)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1786)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1784)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1788)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1777)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1790, 1791)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1827)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1788)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1781)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1778, 1779)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 539, 540)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 548, 549)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 552)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 551, 552)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 550, 551)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 547)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 875)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 7, 8)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 7, 8, 9)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 549, 550)[context]

Sources

Test Your Knowledge

6 quiz questions available for this topic

Start Quiz